Nicola Tufton1,2, Anju Sahdev3, William M Drake1,2, Scott A Akker1,2. 1. Department of Endocrinology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK. 2. Centre for Endocrinology, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK. 3. Department of Radiology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
Abstract
OBJECTIVE: With the discovery that familial phaeochromocytoma and paraganglioma syndrome can be caused by mutations in each subunit of the succinate dehydrogenase enzyme (SDH), has come the recognition that mutations in the individual subunits have their own distinct natural histories. Increased genetic screening is leading to the identification of increasing numbers of, mostly asymptomatic, gene mutation carriers and the implementation of screening strategies for these individuals. Yet there is, to date, no international consensus regarding screening strategies for asymptomatic carriers. DESIGN: A comprehensive PubMed search from 1/1/2000 to 28/2/2018 was undertaken using multiple search terms and subsequently a manual review of references in identified papers to identify all clinically relevant cases and cohorts. In this review, the accumulated, published experience of phenotype and malignancy risks of individual SDH subunits is analysed. Where possible screening results for asymptomatic SDH mutation carriers have been analysed separately to define the penetrance in asymptomatic carriers (asymptomatic penetrance). RESULTS: The combined data confirms that "asymptomatic penetrance" is highest for SDHD and when there is penetrance, the most likely site to develop a PGL is head and neck (SDHD) and extra-adrenal abdominal (SDHB). However, the risk in SDHB carriers of developing HNPGL is also high (35.5%) and a PCC is low (15.1%), and in SDHD carriers there is a high risk of developing a PCC (35.8%) or abdominal PGL (9.4%) and a small, but significant risk at other sympathetic sites. The data suggest that the risk of malignant transformation is the same for both PCC and extra-adrenal abdominal PGLs (30%-35%) in SDHB carriers. In SDHD carriers, the risk of malignant transformation was highest in HNPGLs (7.5%) and similar for sympathetic sites (3.8%-5.2%). CONCLUSIONS: Using this data, we suggest surveillance screening of asymptomatic carriers can be tailored to the underlying SDH subunit and review possible surveillance programmes.
OBJECTIVE: With the discovery that familial phaeochromocytoma and paraganglioma syndrome can be caused by mutations in each subunit of the succinate dehydrogenase enzyme (SDH), has come the recognition that mutations in the individual subunits have their own distinct natural histories. Increased genetic screening is leading to the identification of increasing numbers of, mostly asymptomatic, gene mutation carriers and the implementation of screening strategies for these individuals. Yet there is, to date, no international consensus regarding screening strategies for asymptomatic carriers. DESIGN: A comprehensive PubMed search from 1/1/2000 to 28/2/2018 was undertaken using multiple search terms and subsequently a manual review of references in identified papers to identify all clinically relevant cases and cohorts. In this review, the accumulated, published experience of phenotype and malignancy risks of individual SDH subunits is analysed. Where possible screening results for asymptomatic SDH mutation carriers have been analysed separately to define the penetrance in asymptomatic carriers (asymptomatic penetrance). RESULTS: The combined data confirms that "asymptomatic penetrance" is highest for SDHD and when there is penetrance, the most likely site to develop a PGL is head and neck (SDHD) and extra-adrenal abdominal (SDHB). However, the risk in SDHB carriers of developing HNPGL is also high (35.5%) and a PCC is low (15.1%), and in SDHD carriers there is a high risk of developing a PCC (35.8%) or abdominal PGL (9.4%) and a small, but significant risk at other sympathetic sites. The data suggest that the risk of malignant transformation is the same for both PCC and extra-adrenal abdominal PGLs (30%-35%) in SDHB carriers. In SDHD carriers, the risk of malignant transformation was highest in HNPGLs (7.5%) and similar for sympathetic sites (3.8%-5.2%). CONCLUSIONS: Using this data, we suggest surveillance screening of asymptomatic carriers can be tailored to the underlying SDH subunit and review possible surveillance programmes.
Authors: Laurence Amar; Karel Pacak; Olivier Steichen; Scott A Akker; Simon J B Aylwin; Eric Baudin; Alexandre Buffet; Nelly Burnichon; Roderick J Clifton-Bligh; Patricia L M Dahia; Martin Fassnacht; Ashley B Grossman; Philippe Herman; Rodney J Hicks; Andrzej Januszewicz; Camilo Jimenez; Henricus P M Kunst; Dylan Lewis; Massimo Mannelli; Mitsuhide Naruse; Mercedes Robledo; David Taïeb; David R Taylor; Henri J L M Timmers; Giorgio Treglia; Nicola Tufton; William F Young; Jacques W M Lenders; Anne-Paule Gimenez-Roqueplo; Charlotte Lussey-Lepoutre Journal: Nat Rev Endocrinol Date: 2021-05-21 Impact factor: 43.330
Authors: Karin Eijkelenkamp; Thamara E Osinga; Thera P Links; Anouk N A van der Horst-Schrivers Journal: Clin Genet Date: 2019-05-06 Impact factor: 4.438
Authors: Dahlia F Davidoff; Diana E Benn; Michael Field; Ashley Crook; Bruce G Robinson; Katherine Tucker; Richard De Abreu Lourenco; John R Burgess; Roderick J Clifton-Bligh Journal: J Clin Endocrinol Metab Date: 2022-04-19 Impact factor: 6.134
Authors: Jorge A Carrasquillo; Clara C Chen; Abhishek Jha; Alexander Ling; Frank I Lin; Daniel A Pryma; Karel Pacak Journal: J Nucl Med Date: 2021-08-01 Impact factor: 10.057
Authors: R Garcia-Carbonero; F Matute Teresa; E Mercader-Cidoncha; M Mitjavila-Casanovas; M Robledo; I Tena; C Alvarez-Escola; M Arístegui; M R Bella-Cueto; C Ferrer-Albiach; F A Hanzu Journal: Clin Transl Oncol Date: 2021-05-06 Impact factor: 3.405
Authors: Maria A Pantaleo; Milena Urbini; Angela Schipani; Margherita Nannini; Valentina Indio; Antonio De Leo; Bruno Vincenzi; Antonella Brunello; Giovanni Grignani; Mariaelena Casagrande; Elena Fumagalli; Elena Conca; Maristella Saponara; Elisa Gruppioni; Annalisa Altimari; Dario De Biase; Giovanni Tallini; Gloria Ravegnini; Daniela Turchetti; Marco Seri; Andrea Ardizzoni; Paola Secchiero; Annalisa Astolfi Journal: Front Oncol Date: 2022-01-04 Impact factor: 6.244
Authors: Gemma White; Anand Velusamy; Samantha Anandappa; Michael Masucci; Louise A Breen; Mamta Joshi; Barbara McGowan; Johnathan G H Hubbard; Rupert Obholzer; Dimitra Christodoulou; Audrey Jacques; Philip Touska; Fahim-Ul Hassan; Louise Izatt; Paul V Carroll Journal: Endocr Connect Date: 2022-02-16 Impact factor: 3.335